Sumitomo Mitsui Trust Holdings Inc. Has $513.07 Million Stock Position in Danaher Co. (NYSE:DHR)

Sumitomo Mitsui Trust Holdings Inc. cut its position in Danaher Co. (NYSE:DHR) by 0.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,054,592 shares of the conglomerate’s stock after selling 631 shares during the period. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Danaher were worth $513,073,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in DHR. Cape Investment Advisory Inc. bought a new stake in shares of Danaher during the fourth quarter valued at approximately $25,000. Tsfg LLC grew its position in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares during the period. BKM Wealth Management LLC bought a new stake in Danaher during the 4th quarter valued at $27,000. Wetzel Investment Advisors Inc. acquired a new position in Danaher during the fourth quarter worth $29,000. Finally, Rakuten Securities Inc. bought a new position in shares of Danaher in the fourth quarter valued at $36,000. 79.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

DHR has been the subject of several recent research reports. Evercore ISI decreased their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday. Bank of America increased their price objective on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 24th. TD Cowen lifted their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. HSBC raised Danaher from a “hold” rating to a “buy” rating and increased their price target for the company from $250.00 to $280.00 in a research report on Wednesday, April 17th. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Six equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $268.67.

Danaher Price Performance

Shares of DHR stock traded up $1.95 during trading hours on Wednesday, reaching $242.36. The stock had a trading volume of 444,096 shares, compared to its average volume of 2,855,673. The stock’s fifty day simple moving average is $256.13 and its 200 day simple moving average is $246.86. The firm has a market capitalization of $179.51 billion, a PE ratio of 40.75, a PEG ratio of 3.82 and a beta of 0.84. Danaher Co. has a 12 month low of $182.09 and a 12 month high of $269.11. The company has a current ratio of 1.85, a quick ratio of 1.51 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same period in the previous year, the business earned $2.36 EPS. The business’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, equities research analysts predict that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.27 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of the firm’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the sale, the chief executive officer now owns 115,995 shares in the company, valued at approximately $28,908,273.90. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Brian W. Ellis sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $250.01, for a total value of $1,000,040.00. Following the completion of the sale, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at approximately $7,457,798.30. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 148,783 shares of company stock valued at $37,536,717. 10.90% of the stock is owned by corporate insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.